1-9 of 9
Thalia Farazi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as Second-Line Therapy in Patients with High-Risk Relapsed or Refractory Follicular Lymphoma

Franck Morschhauser, Saurabh Dahiya, M. Lia Palomba, Alejandro Martin Garcia-Sancho, Juan Luis Reguera, John Kuruvilla, Ulrich Jaeger, Guillaume Cartron, Koji Izutsu, Martin Dreyling, Brad S. Kahl, Herve Ghesquieres, Kirit Ardeshna, Hideki Goto, Anna Maria Barbui, Jeremy S. Abramson, Peter Borchmann, Isabelle Fleury, Stephan Mielke, Alan Skarbnik, Sven de Vos, Manali Kamdar, Reem Karmali, Andreas Viardot, Thalia Farazi, Omotayo Fasan, James Lymp, Min Vedal, Rina Nishii, Ariel Avilion, Jessica Papuga, Loretta J. Nastoupil
Journal: Blood
Blood (2023) 142 (Supplement 1): 602.
https://doi.org/10.1182/blood-2023-179474
Published: 2023
Journal Articles

Patient-Reported Outcomes (PROs) from the Phase 2 TRANSCEND FL Study of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory Follicular Lymphoma (FL)

Guillaume Cartron, Alejandro Martin Garcia-Sancho, Juan Luis Reguera, Saurabh Dahiya, Shien Guo, Ling Shi, Laurie Eliason, Jinender Kumar, Thalia Farazi, Omotayo Fasan, Koji Izutsu
Journal: Blood
Blood (2023) 142 (Supplement 1): 668.
https://doi.org/10.1182/blood-2023-180175
Published: 2023
Journal Articles

Matching-Adjusted Indirect Comparison (MAIC) of Efficacy and Safety of Lisocabtagene Maraleucel (liso-cel) and Mosunetuzumab for the Treatment (Tx) of Third Line or Later (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Loretta J. Nastoupil, Ashley Bonner, Pearl Wang, Lamees Almuallem, Jigar Desai, Omotayo Fasan, Thalia Farazi, Jinender Kumar, Saurabh Dahiya
Journal: Blood
Blood (2023) 142 (Supplement 1): 2338.
https://doi.org/10.1182/blood-2023-178786
Published: 2023
Journal Articles

Estimation of Postinfusion Resource Use and Total Costs of Care for Patients with R/R Follicular Lymphoma (FL) Receiving Lisocabtagene Maraleucel (liso-cel) in the TRANSCEND FL Study

Ashley C. Saunders, Tavneet Singh, Abraham Lee, Thalia Farazi, Omotayo Fasan, Sana Mirza, November McGarvey
Journal: Blood
Blood (2023) 142 (Supplement 1): 5084.
https://doi.org/10.1182/blood-2023-178761
Published: 2023
Journal Articles

A Systematic Literature Review (SLR) and Meta-Analysis of Clinical Evidence of Second Line or Later (2L+) Treatments for Follicular Lymphoma (FL) in Adult Patients

Samantha Craigie, Abril Oliva Ramirez, Emily Rosta, Jigar Desai, Omotayo Fasan, Thalia Farazi, Jinender Kumar
Journal: Blood
Blood (2023) 142 (Supplement 1): 6139.
https://doi.org/10.1182/blood-2023-178738
Published: 2023
Journal Articles

Health Care Resource Utilization (HCRU) and Cost of Management of Cytokine Release Syndrome (CRS) and Neurological Events (NEs) in Patients with R/R Follicular Lymphoma (FL) Receiving Lisocabtagene Maraleucel (liso-cel) in the TRANSCEND FL Study

Ashley C. Saunders, Tavneet Singh, Abraham Lee, Thalia Farazi, Omotayo Fasan, Sana Mirza, November McGarvey
Journal: Blood
Blood (2023) 142 (Supplement 1): 7257.
https://doi.org/10.1182/blood-2023-178771
Published: 2023
Journal Articles

Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001

Maria Lia Palomba, MD, Leo I. Gordon, MD, Tanya Siddiqi, MD, Jeremy S. Abramson, MD, Manali Kamdar, MD, Matthew A. Lunning, DO, FACP, David G. Maloney, MD PhD, Charalambos Andreadis, MD MSCE, Jon E. Arnason, MD, Nilanjan Ghosh, MD PhD, Amitkumar Mehta, MD, Scott R. Solomon, MD, Thalia Farazi, MD PhD, Jacob Garcia, MD, Christine Dehner, BSc, Ken Ogasawara, PhD MPH, Jie Gao, PhD, Michael Wang, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 10–11.
https://doi.org/10.1182/blood-2020-136158
Published: 2020
Journal Articles

Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Ineligible Patients: Transcend NHL 001, Outreach, and PILOT

Carlos R. Bachier, MD, Maria Lia Palomba, MD, Jeremy S. Abramson, MD MMSc, Charalambos Andreadis, MD MSCE, Alison R. Sehgal, MD, John Godwin, Gerhard C. Hildebrandt, MD, Tanya Siddiqi, MD, Don Stevens, MD, Thalia Farazi, Ana Kostic, Nikolaus S. Trede, Lei Wang, PhD, James Lymp, PhD, Tennille Thelen, Ken Ogasawara, David G. Maloney, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2868.
https://doi.org/10.1182/blood-2019-127566
Published: 2019
Journal Articles

Results of a Phase Ib Study of Venetoclax Plus R- or G-CHOP in Patients with B-Cell Non-Hodgkin Lymphoma

Andrew D. Zelenetz, MD PhD, Gilles A. Salles, Kylie D Mason, MBBS, FRACP, FRCPA, PhD, Carla Casulo, MD, Steven Le Gouill, MD PhD, Laurie H Sehn, MD, Hervé Tilly, MD PhD, Guillaume Cartron, MD PhD, Martine ED Chamuleau, MD, Andre Goy, MD, Constantine S. Tam, MD, Pieternella J Lugtenburg, MD PhD, Rebecca Elstrom, MD, Thalia Farazi, MD PhD, Juan Liu, Edith Szafer-Glusman, PhD, Mehrdad Mobasher, MD, Franck Morschhauser
Journal: Blood
Blood (2016) 128 (22): 3032.
https://doi.org/10.1182/blood.V128.22.3032.3032
Published: 2016